Bender Robert & Associates’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Bender Robert & Associates’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,000	Closed	-$18.5K	–	56
2023 Q1	$18.5K	Buy	+10,000	New	+$12.4K	0.01%	54
2022 Q4	–	Sell	-10,000	Closed	-$23K	–	55
2022 Q3	$23K	Hold	10,000	–	–	0.01%	52
2022 Q2	$30K	Buy	+10,000	New	+$48.6K	0.01%	53
2021 Q2	–	Sell	-10,000	Closed	-$103K	–	56
2021 Q1	$103K	Buy	+10,000	New	+$110K	0.03%	54

Other funds holding JNCE

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Bender Robert & Associates's JNCE Position: Q2 2023 in Review

Bender Robert & Associates sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 10,000 shares — an estimated $18.5K sold.

Bender Robert & Associates first reported a position in JNCE in Q1 2021 and held it in 4 quarters. The position peaked at $103K in Q1 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

Bender Robert & Associates reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Bender Robert & Associates sold 10,000 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $18.5K.
Bender Robert & Associates first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
Bender Robert & Associates's Jounce Therapeutics, Inc. Common Stock position peaked at $103K in Q1 2021.
1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Bender Robert & Associates's 13F filing for Q2 2023, filed 14 Jul 2023.